Files
Download Full Text (252 KB)
Description
Acute Ischemic Stroke (AIS) is a leading cause of disability and death in the United States, requiring urgent treatment1,2; earlier treatment improves patient outcomes.
Fibrinolytic agents including alteplase and tenecteplase (TNK) reduce long-term disability in AIS but are associated with hemorrhagic risks3,4.
As of January 2024, Corewell Health East hospitals updated their guidelines that TNK would be the first line agent in the treatment of AIS.
Alteplase is the only approved agent for AIS, but TNK shows similar effectiveness along with shorter preparation and administration time which may ultimately improve door-to-needle time2 .
Careful consideration of patient characteristics is important to minimize hemorrhagic risk: blood pressure (BP), surgical history, head imaging, medications prior to symptom onset, and National Institutes of Health Stroke Scale (NIHSS).
The American Heart Association (AHA) and American Stroke Association (ASA) recommend a door-to needle time of 60 minutes or less, and a medication order entry to thrombolytic treatment of 45 minutes or less1,2.
Publication Date
12-2024
Keywords
acute, ischemic, stroke
Disciplines
Pharmacy and Pharmaceutical Sciences
Recommended Citation
Alsarraf I, Pilotto J, Baker RE, Reich E. Tenecteplase for acute ischemic stroke: insights from a large community teaching hospital. Presented at: 2024 ASHP Midyear Clinical Meeting; 2024 December 7-12; New Orleans, LA.
Comments
2024 ASHP Midyear Clinical Meeting, December 7-12, 2024, New Orleans, LA.